[CMRX] Chimerix, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 4.75 Change: 0.2 (4.4%)
Ext. hours: Change: 0 (0%)

chart CMRX

Refresh chart

Strongest Trends Summary For CMRX

CMRX is in the medium-term down -52% below S&P in 1 year. In the long-term down -76% below S&P in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel, oral antivirals to address unmet medical needs in the United States. Its lead compounds include brincidofovir (CMX001), which is in Phase III clinical development; CMX157, a nucleotide analog that has completed Phase I study for the treatment of HIV infections. The company?s proprietary lipid technology and chemical library is under discovery and preclinical stage of development. It has collaboration and license agreement with Merck Sharp & Dohme Corp. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 34.71% Sales Growth - Q/Q7.09% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-25.97% ROE-27.65% ROI
Current Ratio10.78 Quick Ratio Long Term Debt/Equity Debt Ratio0.06
Gross Margin Operating Margin-1578.72% Net Profit Margin-1582.88% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities700 K Cash From Investing Activities-54.72 M Cash From Operating Activities-18.84 M Gross Profit
Net Profit-22.27 M Operating Profit-22.33 M Total Assets274.12 M Total Current Assets177.26 M
Total Current Liabilities16.44 M Total Debt2.89 M Total Liabilities16.6 M Total Revenue1.24 M
Technical Data
High 52 week4.5 Low 52 week1.79 Last close2.85 Last change-2.06%
RSI20.45 Average true range0.2 Beta1.19 Volume236.01 K
Simple moving average 20 days-16.23% Simple moving average 50 days-19.14% Simple moving average 200 days-2.97%
Performance Data
Performance Week-13.64% Performance Month-22.76% Performance Quart-8.65% Performance Half29.55%
Performance Year-34.93% Performance Year-to-date10.89% Volatility daily3.18% Volatility weekly7.11%
Volatility monthly14.56% Volatility yearly50.45% Relative Volume181.52% Average Volume419.6 K
New High New Low


2020-05-28 08:00:10 | Chimerix to Present at Jefferies Virtual Healthcare Conference

2020-05-12 06:47:02 | Revenue Downgrade: Here's What Analysts Forecast For Chimerix, Inc. NASDAQ:CMRX

2020-05-07 10:25:02 | Chimerix CMRX Reports Q1 Loss, Lags Revenue Estimates

2020-05-07 09:07:00 | Recap: Chimerix Q1 Earnings

2020-05-07 07:00:10 | Chimerix Reports First Quarter 2020 Financial Results and Provides Operational Update

2020-05-02 08:40:26 | One Thing To Remember About The Chimerix, Inc. NASDAQ:CMRX Share Price

2020-04-29 07:00:10 | Chimerix Announces Initiation of a Phase 2/3 Study of DSTAT in Acute Lung Injury for Patients with Severe COVID-19

2020-04-28 16:30:10 | Chimerix Receives FDA Clearance for Rolling Submission of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox

2020-03-18 06:26:57 | Michael Sherman Is The CEO, President & Director of Chimerix, Inc. NASDAQ:CMRX And They Just Spent US$106k On Shares

2020-03-04 23:36:37 | Edited Transcript of CMRX earnings conference call or presentation 25-Feb-20 1:30pm GMT

2020-02-28 12:00:05 | All You Need to Know About Chimerix CMRX Rating Upgrade to Buy

2020-02-26 08:00:10 | Chimerix to Present at Cowen and Company 40th Annual Health Care Conference

2020-02-25 07:00:10 | Chimerix Reports Fourth Quarter and Year End 2019 Financial Results and Provides Operational Update

2020-02-25 06:30:00 | Chimerix, Inc. to Host Earnings Call

2020-02-24 08:00:10 | Chimerix Appoints Pratik S. Multani, M.D., to Board of Directors

2020-02-18 08:00:10 | Chimerix to Report Fourth Quarter and Year End 2019 Financial Results and Provide an Operational Update on February 25, 2020

2020-02-06 07:04:33 | Investors Who Bought Chimerix NASDAQ:CMRX Shares Five Years Ago Are Now Down 96%

2020-02-05 11:52:05 | Steven Cohen Renews His Interest in Verastem

2020-01-29 08:00:10 | Chimerix Presents Data Supporting Brincidofovir as a Potential Treatment for Smallpox at 2020 American Society for Microbiology Biothreats Meeting

2020-01-03 11:30:04 | Has Chimerix CMRX Outpaced Other Medical Stocks This Year?

2019-12-23 06:12:44 | Here's Why We're Watching Chimerix's NASDAQ:CMRX Cash Burn Situation

2019-12-16 01:04:14 | New Trade Deal, New Records for S&P and NASDAQ

2019-12-14 20:59:21 | Is Chimerix Inc CMRX A Good Stock To Buy?

2019-12-10 07:30:10 | Chimerix Presents Updated Results from Phase 2 Clinical Trial of DSTAT in Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia at American Society of Hematology Annual Meeting

2019-12-04 01:01:26 | Stocks Not Happy About Talk of Trade Deal Delay

2019-11-11 20:58:53 | Edited Transcript of CMRX earnings conference call or presentation 5-Nov-19 1:30pm GMT

2019-11-07 06:19:51 | Should You Be Concerned About Chimerix, Inc.'s NASDAQ:CMRX Historical Volatility?

2019-11-05 07:00:00 | Chimerix Announces Third Quarter 2019 Financial Results and Provides Operational Update

2019-11-04 16:01:00 | Chimerix to Present at Upcoming Investor Conferences

2019-10-29 08:00:05 | Chimerix to Announce Third Quarter 2019 Financial Results and Provide an Operational Update on November 5, 2019

2019-10-02 08:47:45 | Have Insiders Been Buying Chimerix, Inc. NASDAQ:CMRX Shares?

2019-10-01 08:10:27 | The Daily Biotech Pulse: Safety Scare For Anaptys' Psoriasis Drug, NewLink Genetics To Merge With Lumos, Insider Buy Props Up VBI Vaccines

2019-09-30 19:30:00 | Chimerix Announces Exclusive Global License Agreement with SymBio Pharmaceuticals for Brincidofovir

2019-09-27 08:00:00 | Chimerix to Present at 2019 Cantor Global Healthcare Conference

2019-08-27 13:13:36 | Those Who Purchased Chimerix NASDAQ:CMRX Shares Five Years Ago Have A 91% Loss To Show For It

2019-08-08 09:35:01 | Chimerix CMRX Reports Q2 Loss, Lags Revenue Estimates

2019-08-08 08:00:00 | Chimerix Announces Second Quarter 2019 Financial Results and Operational Update

2019-08-07 10:30:02 | Chimerix CMRX Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

2019-08-05 07:55:16 | Durham pharma spends $30 million for rights to potential Leukemia treatment

2019-07-31 07:00:00 | Chimerix Announces Exclusive Worldwide License of Phase 3 Ready CX-01 for Development in Acute Myeloid Leukemia

2019-07-12 15:07:33 | Do Institutions Own Chimerix, Inc. NASDAQ:CMRX Shares?

2019-06-28 18:41:45 | Did Hedge Funds Drop The Ball On Chimerix Inc CMRX ?

2019-05-16 09:11:01 | Will Chimerix to Surge Higher?

2019-05-09 14:08:22 | Edited Transcript of CMRX earnings conference call or presentation 9-May-19 12:30pm GMT

2019-05-09 09:25:01 | Chimerix CMRX Reports Q1 Loss, Tops Revenue Estimates

2019-05-09 08:25:59 | Chimerix: 1Q Earnings Snapshot

2019-05-09 08:00:00 | Chimerix Announces First Quarter 2019 Financial Results and Strategy Update

2019-05-09 06:30:00 | Chimerix, Inc. to Host Earnings Call

2019-05-02 16:01:00 | Chimerix to Announce First Quarter 2019 Financial Results on May 9, 2019

2019-04-29 10:31:02 | Will Chimerix CMRX Report Negative Q1 Earnings? What You Should Know